Hemophilia Market Size to Surpass US$ 22.3 Billion by 2028 at 11.1% CAGR

PRESS RELEASE

Published March 28, 2023

IMARC Group has recently released a new research study titled "Hemophilia Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028", The global hemophilia market size reached US$ 11.7 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 22.3 Billion by 2028, exhibiting a growth rate (CAGR) of 11.1% during 2023-2028. This report can serve as an excellent guide for investors, researchers, consultants, marketing strategists and all those who are planning to foray into the market in any form.

Hemophilia is a genetic medical condition that impacts the blood clotting mechanism of the body. It causes abnormal blood clots, leading to excessive bleeding, easy bruising, and oozing after an injury, surgery, or dental procedure. It occurs due to a hereditary deficiency in coagulation factor that inhibits blood clotting by limiting the availability of necessary blood-clotting proteins. Its treatment primarily focuses on replacing the missing proteins and preventing potential complications. At present, hemophilia can be treated through medications, replacement therapy, and injections of a clotting factor or plasma across the globe.

Request for a free sample copy of this report: https://www.imarcgroup.com/hemophilia-market/requestsample

Hemophilia Market Trends and Drivers:

The global hemophilia market is primarily driven by the increasing number of patients with hemophilia and a rise in genetic abnormalities across the globe. Additionally, the surging popularity of prophylactic treatment and the rising diagnosis rate of illness is positively influencing the market growth. Moreover, several favorable initiatives by governments of numerous countries to spread awareness about the benefits of early diagnosis and proper procedures for early screening of neonates have catalyzed market growth. Furthermore, several key players are focusing on introducing technologically advanced diagnostic tools and therapies to improve the effectiveness and precision of hemophilia treatment, thereby contributing to market growth. Other factors, including increasing funding for research and development (R&D) activities, the rapid expansion of specialized hemophilia treatment centers (HTCs), and rising demand for early diagnosis of hemophilia, are also anticipated to drive the market further.

Report Segmentation:

The report has segmented the market into the following categories:

Breakup by Type:

Hemophilia A
Hemophilia B
Hemophilia C
Others

Breakup by Treatment:

On-Demand
Prophylaxis

Breakup by Therapy:

Replacement Therapy
ITI Therapy
Gene Therapy

Market Breakup by Region:

North America (United States, Canada)
Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
Latin America (Brazil, Mexico, Others)
Middle East and Africa

Competitive Landscape with Key Player:

Baxter International Inc.
Bayer AG
BioMarin Pharmaceutical Inc.
CSL Behring (CSL Limited)
F. Hoffmann-La Roche AG
Grifols S.A.
Kedrion S.p.A.
Novo Nordisk A/S
Octapharma AG
Pfizer Inc.
Sanofi S.A.
Takeda Pharmaceutical Company Limited.

Ask Analyst for 10% Free Customized Report: https://www.imarcgroup.com/request?type=report&id=4508&flag=C

If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Our offerings include comprehensive market intelligence in the form of research reports, production cost reports, feasibility studies, and consulting services. Our team, which includes experienced researchers and analysts from various industries, is dedicated to providing high-quality data and insights to our clientele, ranging from small and medium businesses to Fortune 1000 corporations.

Contact US

IMARC Group

Email: sales@imarcgroup.com

USA: +1-631-791-1145 | Asia: +91-120-433-0800

Address: 134 N 4th St. Brooklyn, NY 11249, USA